{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T20:42:59Z","timestamp":1775594579061,"version":"3.50.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.expneurol.2020.113514","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T05:19:32Z","timestamp":1603430372000},"page":"113514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease"],"prefix":"10.1016","volume":"335","author":[{"given":"Jay S.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney A.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Keibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel W.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom H.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry D.","family":"Waterhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandhya","family":"Kortagere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.expneurol.2020.113514_bb0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/09084282.2010.547777","article-title":"Sustained attention and behavioral characteristics associated with ADHD in adults","volume":"18","author":"Avisar","year":"2011","journal-title":"Appl. Neuropsychol."},{"issue":"1","key":"10.1016\/j.expneurol.2020.113514_bb0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00213-013-3141-6","article-title":"Noradrenergic versus dopaminergic modulation of impulsivity, attention and monitoring behaviour in rats performing the stop-signal task: possible relevance to ADHD","volume":"230","author":"Bari","year":"2013","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.expneurol.2020.113514_bb0015","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/0006-8993(74)90948-2","article-title":"Histochemical confirmation for dopaminergic innervation of the rat cerebral cortex after destruction of the noradrenergic ascending pathways","volume":"81","author":"Berger","year":"1974","journal-title":"Brain Res."},{"issue":"10","key":"10.1016\/j.expneurol.2020.113514_bb0020","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.biopsych.2006.04.022","article-title":"Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function","volume":"60","author":"Berridge","year":"2006","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.expneurol.2020.113514_bb0025","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm875","article-title":"Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function","volume":"9","author":"Bezard","year":"2003","journal-title":"Nat. Med."},{"issue":"Pt B","key":"10.1016\/j.expneurol.2020.113514_bb0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.brainres.2016.01.001","article-title":"Age-related changes in prefrontal norepinephrine transporter density: the basis for improved cognitive flexibility after low doses of atomoxetine in adolescent rats","volume":"1641","author":"Bradshaw","year":"2016","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.expneurol.2020.113514_bb0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0166-2236(90)90058-I","article-title":"Cognitive function in Parkinson\u2019s disease: from description to theory","volume":"13","author":"Brown","year":"1990","journal-title":"Trends Neurosci."},{"issue":"4","key":"10.1016\/j.expneurol.2020.113514_bb0040","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00702-002-0811-7","article-title":"Pramipexole in comparison to l-dopa: a neuropsychological study","volume":"110","author":"Brusa","year":"2003","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"4","key":"10.1016\/j.expneurol.2020.113514_bb0045","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.dcn.2011.04.003","article-title":"Atomoxetine facilitates attentional set shifting in adolescent rats","volume":"1","author":"Cain","year":"2011","journal-title":"Dev. Cogn. Neurosci."},{"key":"10.1016\/j.expneurol.2020.113514_bb0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.neuropharm.2019.05.016","article-title":"Atomoxetine improves memory and other components of executive function in young-adult rats and aged rhesus monkeys","volume":"155","author":"Callahan","year":"2019","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"10.1016\/j.expneurol.2020.113514_bb0055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1615\/CritRevNeurobiol.v16.i12.130","article-title":"Dopamine reuptake by norepinephrine neurons: exception or rule?","volume":"16","author":"Carboni","year":"2004","journal-title":"Crit. Rev. Neurobiol."},{"issue":"24","key":"10.1016\/j.expneurol.2020.113514_bb0060","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1523\/JNEUROSCI.0310-17.2017","article-title":"D3 receptors regulate excitability in a unique class of prefrontal pyramidal cells","volume":"37","author":"Clarkson","year":"2017","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.expneurol.2020.113514_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2005.03.024","article-title":"Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson\u2019s disease","volume":"30","author":"Cools","year":"2006","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"Pt 5","key":"10.1016\/j.expneurol.2020.113514_bb0070","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1093\/brain\/114.5.2095","article-title":"Cognitive impairment in early, untreated Parkinson\u2019s disease and its relationship to motor disability","volume":"114","author":"Cooper","year":"1991","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.expneurol.2020.113514_bb0075","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1176\/jnp.16.1.63","article-title":"Neurometabolic functioning and neuropsychological correlates in children with ADHD-H: preliminary findings","volume":"16","author":"Courvoisie","year":"2004","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.expneurol.2020.113514_bb0080","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s12031-015-0491-z","article-title":"Impaired energy metabolism and disturbed dopamine and glutamate signalling in the striatum and prefrontal cortex of the spontaneously hypertensive rat model of attention-deficit hyperactivity disorder","volume":"56","author":"Dimatelis","year":"2015","journal-title":"J. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.expneurol.2020.113514_bb0085","first-page":"102","article-title":"Changes in dopaminergic neurons of the mesocorticolimbic system in Parkinson\u2019s disease","volume":"34","author":"Dymecki","year":"1996","journal-title":"Folia Neuropathol."},{"issue":"1","key":"10.1016\/j.expneurol.2020.113514_bb0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1017\/S1041610205002450","article-title":"Impact of cognitive impairment on mild dementia patients and mild cognitive impairment patients and their informants","volume":"18","author":"Frank","year":"2006","journal-title":"Int. Psychogeriatr."},{"issue":"1\u20133","key":"10.1016\/j.expneurol.2020.113514_bb0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2003.08.096","article-title":"Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson\u2019s disease","volume":"480","author":"Guillin","year":"2003","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.expneurol.2020.113514_bb0100","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/mds.25857","article-title":"The neurobiological basis of cognitive impairment in Parkinson\u2019s disease","volume":"29","author":"Halliday","year":"2014","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.expneurol.2020.113514_bb0105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-0404.1986.tb03257.x","article-title":"Cognitive performance in early Parkinson\u2019s disease","volume":"73","author":"Hietanen","year":"1986","journal-title":"Acta Neurol. Scand."},{"issue":"12","key":"10.1016\/j.expneurol.2020.113514_bb0110","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1586\/ern.12.131","article-title":"Neurobiology of cognitive impairment in Parkinson\u2019s disease","volume":"12","author":"Jellinger","year":"2012","journal-title":"Expert. Rev. Neurother."},{"issue":"13","key":"10.1016\/j.expneurol.2020.113514_bb0115","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1359-6446(05)03491-4","article-title":"Dopamine D3 receptor antagonists as therapeutic agents","volume":"10","author":"Joyce","year":"2005","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.expneurol.2020.113514_bb0120","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41598-017-02420-w","article-title":"Early-onset mild cognitive impairment in Parkinson\u2019s disease: altered corticopetal cholinergic network","volume":"7","author":"Kim","year":"2017","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.expneurol.2020.113514_bb0125","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hbm.22006","article-title":"Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson\u2019s disease","volume":"34","author":"Ko","year":"2013","journal-title":"Hum. Brain Mapp."},{"issue":"2","key":"10.1016\/j.expneurol.2020.113514_bb0130","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3171\/2018.11.JNS182386","article-title":"Nucleus basalis of Meynert neuronal activity in Parkinson\u2019s disease","volume":"132","author":"Lee","year":"2019","journal-title":"J. Neurosurg."},{"issue":"2","key":"10.1016\/j.expneurol.2020.113514_bb0135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0028-3908(03)00145-X","article-title":"The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade","volume":"45","author":"Leriche","year":"2003","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.expneurol.2020.113514_bb0140","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1212\/WNL.39.4.557","article-title":"Cognitive impairments associated with early Parkinson\u2019s disease","volume":"39","author":"Levin","year":"1989","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.expneurol.2020.113514_bb0145","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000438824","article-title":"Impact of Rivastigmine on cognitive dysfunction and falling in Parkinson\u2019s disease patients","volume":"74","author":"Li","year":"2015","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.expneurol.2020.113514_bb0150","first-page":"1","article-title":"The organization of the ascending catecholamine neuron systems in the rat brain as revealed by the glyoxylic acid fluorescence method","volume":"412","author":"Lindvall","year":"1974","journal-title":"Acta Physiol. Scand. Suppl."},{"issue":"3","key":"10.1016\/j.expneurol.2020.113514_bb0155","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.expneurol.2020.113514_bb0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.euroneuro.2008.07.012","article-title":"Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists","volume":"19","author":"Loiseau","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.expneurol.2020.113514_bb0165","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuropharm.2019.01.003","article-title":"Selective activation of dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention","volume":"148","author":"Marshall","year":"2019","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.expneurol.2020.113514_bb0170","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1007\/s00415-018-8913-9","article-title":"Correlation among olfactory function, motors\u2019 symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson\u2019s disease","volume":"265","author":"Masala","year":"2018","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.expneurol.2020.113514_bb0175","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ana.10078","article-title":"Dopaminergic modulation of cortical function in patients with Parkinson\u2019s disease","volume":"51","author":"Mattay","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2020.113514_bb0180","article-title":"The impact of clinical and cognitive variables on social functioning in Parkinson\u2019s disease: patient versus examiner estimates","volume":"2010","author":"McNamara","year":"2010","journal-title":"Parkinsons. Dis."},{"issue":"8","key":"10.1016\/j.expneurol.2020.113514_bb0185","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1017\/S1461145710000775","article-title":"The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures","volume":"13","author":"Millan","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"15","key":"10.1016\/j.expneurol.2020.113514_bb0190","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1007\/s00213-014-3479-4","article-title":"Aberrant glutamate signaling in the prefrontal cortex and striatum of the spontaneously hypertensive rat model of attention-deficit\/hyperactivity disorder","volume":"231","author":"Miller","year":"2014","journal-title":"Psychopharmacology"},{"issue":"Pt 1","key":"10.1016\/j.expneurol.2020.113514_bb0195","first-page":"233","article-title":"Cortical activity in Parkinson\u2019s disease during executive processing depends on striatal involvement","volume":"130","author":"Monchi","year":"2007","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.expneurol.2020.113514_bb0200","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1046\/j.1460-9568.1998.00264.x","article-title":"Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies","volume":"10","author":"Morissette","year":"1998","journal-title":"Eur. J. Neurosci."},{"issue":"2","key":"10.1016\/j.expneurol.2020.113514_bb0205","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1523\/JNEUROSCI.22-02-00389.2002","article-title":"Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines","volume":"22","author":"Moron","year":"2002","journal-title":"J. Neurosci."},{"issue":"11","key":"10.1016\/j.expneurol.2020.113514_bb0210","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S1388-2457(01)00653-8","article-title":"Delay of simple reaction time after levodopa intake","volume":"112","author":"Muller","year":"2001","journal-title":"Clin. Neurophysiol."},{"issue":"8","key":"10.1016\/j.expneurol.2020.113514_bb0215","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.euroneuro.2013.05.006","article-title":"The potential role of dopamine D(3) receptor neurotransmission in cognition","volume":"23","author":"Nakajima","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.expneurol.2020.113514_bb0220","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1515\/revneuro-2013-0004","article-title":"Prefrontal dopamine signaling and cognitive symptoms of Parkinson\u2019s disease","volume":"24","author":"Narayanan","year":"2013","journal-title":"Rev. Neurosci."},{"issue":"7","key":"10.1016\/j.expneurol.2020.113514_bb0225","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/syn.20325","article-title":"Dopamine (D2\/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo","volume":"60","author":"Narendran","year":"2006","journal-title":"Synapse"},{"issue":"21 Suppl 4","key":"10.1016\/j.expneurol.2020.113514_bb0230","first-page":"S1","article-title":"The scientific and clinical basis for the treatment of Parkinson disease (2009)","volume":"72","author":"Olanow","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.expneurol.2020.113514_bb0235","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/1073858404266776","article-title":"Cognitive dysfunction in Parkinson\u2019s disease: the role of frontostriatal circuitry","volume":"10","author":"Owen","year":"2004","journal-title":"Neuroscientist"},{"issue":"Pt 6","key":"10.1016\/j.expneurol.2020.113514_bb0240","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/brain\/115.6.1727","article-title":"Fronto-striatal cognitive deficits at different stages of Parkinson\u2019s disease","volume":"115","author":"Owen","year":"1992","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2020.113514_bb0245","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2017.11.334","article-title":"Olfactory dysfunctions in drug-naive Parkinson\u2019s disease with mild cognitive impairment","volume":"46","author":"Park","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"issue":"5","key":"10.1016\/j.expneurol.2020.113514_bb0250","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1017\/S1355617708081010","article-title":"Levodopa and executive performance in Parkinson\u2019s disease: a randomized study","volume":"14","author":"Pascual-Sedano","year":"2008","journal-title":"J. Int. Neuropsychol. Soc."},{"issue":"12","key":"10.1016\/j.expneurol.2020.113514_bb0255","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1007\/s00213-019-05329-6","article-title":"The use of reaction time distributions to study attention in male rats: the effects of atomoxetine and guanfacine","volume":"236","author":"Redding","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.expneurol.2020.113514_bb0260","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1744-9081-2-41","article-title":"The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of attention-deficit\/hyperactivity disorder (ADHD)","volume":"2","author":"Sagvolden","year":"2006","journal-title":"Behav. Brain Funct."},{"issue":"1\u20132","key":"10.1016\/j.expneurol.2020.113514_bb0265","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0166-4328(88)90050-2","article-title":"Vasopressin and amphetamine, but not desglycinamide vasopressin, impair positively reinforced visual attention performance in rats","volume":"29","author":"Sahgal","year":"1988","journal-title":"Behav. Brain Res."},{"issue":"12","key":"10.1016\/j.expneurol.2020.113514_bb0270","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1523\/JNEUROSCI.22-12-05198.2002","article-title":"Cognitive slowing in Parkinson\u2019s disease: a behavioral evaluation independent of motor slowing","volume":"22","author":"Sawamoto","year":"2002","journal-title":"J. Neurosci."},{"issue":"13","key":"10.1016\/j.expneurol.2020.113514_bb0275","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/01.wnl.0000257821.28992.db","article-title":"Cognitive slowing in Parkinson disease is accompanied by hypofunctioning of the striatum","volume":"68","author":"Sawamoto","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.expneurol.2020.113514_bb0280","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/1055-8330(95)90014-4","article-title":"Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey","volume":"4","author":"Schneider","year":"1995","journal-title":"Neurodegeneration"},{"issue":"2","key":"10.1016\/j.expneurol.2020.113514_bb0285","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0006-8993(93)90049-S","article-title":"Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys","volume":"615","author":"Schneider","year":"1993","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.expneurol.2020.113514_bb0290","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/ana.410430308","article-title":"Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment","volume":"43","author":"Schneider","year":"1998","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.expneurol.2020.113514_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2004.05.006","article-title":"The principal features and mechanisms of dopamine modulation in the prefrontal cortex","volume":"74","author":"Seamans","year":"2004","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.expneurol.2020.113514_bb0300","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.neuropharm.2015.04.004","article-title":"In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson\u2019s disease","volume":"100","author":"Simms","year":"2016","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.expneurol.2020.113514_bb0305","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/ejn.13390","article-title":"The dopamine D3 receptor, a quarter century later","volume":"45","author":"Sokoloff","year":"2017","journal-title":"Eur. J. Neurosci."},{"issue":"6289","key":"10.1016\/j.expneurol.2020.113514_bb0310","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/347146a0","article-title":"Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics","volume":"347","author":"Sokoloff","year":"1990","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.expneurol.2020.113514_bb0315","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/187152706784111551","article-title":"The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders","volume":"5","author":"Sokoloff","year":"2006","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"2","key":"10.1016\/j.expneurol.2020.113514_bb0320","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00210-012-0797-0","article-title":"Direct and indirect interactions of the dopamine D(3) receptor with glutamate pathways: implications for the treatment of schizophrenia","volume":"386","author":"Sokoloff","year":"2013","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"10","key":"10.1016\/j.expneurol.2020.113514_bb0325","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1111\/j.1460-9568.1997.tb01375.x","article-title":"Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine","volume":"9","author":"Tanda","year":"1997","journal-title":"Eur. J. Neurosci."},{"issue":"4111","key":"10.1016\/j.expneurol.2020.113514_bb0330","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1126\/science.182.4111.499","article-title":"Dopaminergic terminals in the rat cortex","volume":"182","author":"Thierry","year":"1973","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.expneurol.2020.113514_bb0335","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3181\/0707-MR-193","article-title":"Current management of the cognitive dysfunction in Parkinson\u2019s disease: how far have we come?","volume":"233","author":"Vale","year":"2008","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"11","key":"10.1016\/j.expneurol.2020.113514_bb0340","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1136\/jnnp.2006.112367","article-title":"Cognitive impairment in Parkinson\u2019s disease","volume":"78","author":"Verbaan","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.expneurol.2020.113514_bb0345","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11910-018-0823-9","article-title":"Mild cognitive impairment in Parkinson\u2019s disease-what is it?","volume":"18","author":"Weil","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"4","key":"10.1016\/j.expneurol.2020.113514_bb0350","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/cercor\/8.4.321","article-title":"Widespread origin of the primate mesofrontal dopamine system","volume":"8","author":"Williams","year":"1998","journal-title":"Cereb. Cortex"},{"issue":"Pt 7","key":"10.1016\/j.expneurol.2020.113514_bb0355","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/brain\/awm111","article-title":"Evolution of cognitive dysfunction in an incident Parkinson\u2019s disease cohort","volume":"130","author":"Williams-Gray","year":"2007","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.expneurol.2020.113514_bb0360","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acschemneuro.6b00221","article-title":"Functional characterization of a novel series of biased Signaling dopamine D3 receptor agonists","volume":"8","author":"Xu","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.expneurol.2020.113514_bb0365","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.phrs.2019.03.003","article-title":"Biased signaling agonist of dopamine D3 receptor induces receptor internalization independent of beta-arrestin recruitment","volume":"143","author":"Xu","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"14","key":"10.1016\/j.expneurol.2020.113514_bb0370","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/mds.23932","article-title":"The interplay of cholinergic function, attention, and falls in Parkinson\u2019s disease","volume":"26","author":"Yarnall","year":"2011","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.expneurol.2020.113514_bb0375","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/ageing\/aft085","article-title":"Mild cognitive impairment in Parkinson\u2019s disease","volume":"42","author":"Yarnall","year":"2013","journal-title":"Age Ageing"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488620303459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488620303459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T06:04:13Z","timestamp":1758002653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488620303459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":75,"alternative-id":["S0014488620303459"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2020.113514","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2020.113514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113514"}}